Indivior (LSE:INDV) Total Receivables : £196.0 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Indivior Total Receivables?

Indivior's Total Receivables for the quarter that ended in Mar. 2024 was £196.0 Mil.

Indivior Total Receivables Historical Data

The historical data trend for Indivior's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indivior Total Receivables Chart

Indivior Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Receivables

Get a 7-Day Free Trial

146.50

133.18

151.90

180.62

200.66

Indivior Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Receivables	Get a 7-Day Free Trial															175.51	181.37	197.96	200.66	195.96

Indivior Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Indivior Total Receivables Related Terms

Thank you for viewing the detailed overview of Indivior's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Indivior (LSE:INDV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indivior PLC (LSE:INDV) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

INDV:USA INDVl:UK 2IVB:Germany

Address

234 Bath Road, Slough, Berkshire, GBR, SL1 4EE

Website

http://www.indivior.com

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.